Catalog No.
DHD16102
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG2-kappa
Clonality
Monoclonal
Target
PDGFR2, Platelet-derived growth factor receptor alpha, RHEPDGFRA, Alpha platelet-derived growth factor receptor, PDGFR-2, Platelet-derived growth factor alpha receptor, Platelet-derived growth factor receptor 2, PDGF-R-alpha, Alpha-type platelet-derived growth factor receptor, CD140a antigen, CD140 antigen-like family member A, PDGFRA, PDGFR-alpha, CD140a
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P16234
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
MEDI-575, CAS: 1243266-04-7
Clone ID
Tovetumab
A Novel Pharmacodynamic Biomarker and Mechanistic Modeling Facilitate the Development of Tovetumab, a Monoclonal Antibody Directed Against Platelet-Derived Growth Factor Receptor Alpha, for Cancer Therapy, PMID: 33210183
Discontinued in 2013: oncology drugs, PMID: 25315907
Phase II study of MEDI-575, an anti-platelet-derived growth factor-α antibody, in patients with recurrent glioblastoma, PMID: 27844311
Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Patients With Previously Untreated Advanced Non-Small-Cell Lung Cancer, PMID: 30685114
A Phase I study of MEDI-575, a PDGFRα monoclonal antibody, in Japanese patients with advanced solid tumors, PMID: 26223436
A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors, PMID: 25149088
Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells., PMID:33419761
A Novel Pharmacodynamic Biomarker and Mechanistic Modeling Facilitate the Development of Tovetumab, a Monoclonal Antibody Directed Against Platelet-Derived Growth Factor Receptor Alpha, for Cancer Therapy., PMID:33210183
Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Patients With Previously Untreated Advanced Non-Small-Cell Lung Cancer., PMID:30685114
Phase II study of MEDI-575, an anti-platelet-derived growth factor-α antibody, in patients with recurrent glioblastoma., PMID:27844311
A Phase I study of MEDI-575, a PDGFRα monoclonal antibody, in Japanese patients with advanced solid tumors., PMID:26223436
Discontinued in 2013: oncology drugs., PMID:25315907
A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors., PMID:25149088
For research use only. Not for human or drug use.
